Lessons from COVID-19 mortality data across countries
- PMID: 33657587
- PMCID: PMC9584045
- DOI: 10.1097/HJH.0000000000002833
Lessons from COVID-19 mortality data across countries
Abstract
Objective: Several online sources provide up-to-date open-access data on numbers, rates and proportions of COVID-19 deaths. Our article aims of comparing and interpreting between-country trends of mortality rate, case-fatality and all-cause excess mortality.
Methods: We used data from open databases (Our World in Data mostly) for comparing mortality of eleven western countries (Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, Sweden, UK, USA). Between-country trends in mortality rate and case-fatality (both including deaths for COVID-19 as numerator and therefore labelled as COVID-19 mortality metrics) and all-cause excess mortality (i.e. observed deaths during the epidemic compared with those expected based on mortality in the same periods of previous years) were compared.
Results: Although Belgium ranks first in mortality from COVID-19 (possibly due to the broadest criterion for attributing a death to COVID-19), it does not rank first for all-cause excess mortality. Conversely, compared with Belgium, the UK, Italy and Spain have reported lower COVID-19 mortality (possibly due to the narrower definitions for a COVID-19 death) but higher all-cause excess mortality. Germany and Austria are the unique countries for which COVID-19 mortality, case-fatality and all-cause excess mortality consistently exhibited the lowest rates.
Conclusion: Between-country heterogeneity of COVID-19 mortality metrics could be largely explained by differences of criteria for attributing a death to COVID-19; in age/comorbidity structures; in policies for identifying asymptomatic people affected from SARS-CoV-2 infection. All-cause excess mortality is recommended as a more reliable metric for comparing countries.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
G.C. received research support from the European Community (EC), the Italian Agency of Drug (AIFA) and the Italian Ministry of Education, University and Research (MIUR). He took part to a variety of projects that were funded by pharmaceutical companies (i.e. Novartis, GSK, Roche, AMGEN and BMS). He also received honoraria as member of Advisory Board from Roche.
For the remaining authors, none were declared.
G.C. received research support from the European Community (EC), the Italian Agency of Drug (AIFA) and the Italian Ministry of Education, University and Research (MIUR). He took part to a variety of projects that were funded by pharmaceutical companies (i.e. Novartis, GSK, Roche, AMGEN and BMS). He also received honoraria as member of Advisory Board from Roche.
For the remaining authors, none were declared.
Figures


References
-
- Karanikolos M, McKee M. How comparable is covid-19 mortality across countries? Eurohealth 2020; 26:45–50.
-
- World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/ [Accessed 26 December 2020].
-
- Johns Hopkins University of Medicine. Coronavirus Research Center. Mortality analyses. https://coronavirus.jhu.edu/data/mortality [Accessed 26 December 2020].
-
- European Centre for Disease Prevention and Control. COVID-19 situation dashboard. https://qap.ecdc.europa.eu/public/extensions/COVID-19/COVID-19.html#glob... [Accessed 26 December 2020].
-
- Our World in Data. Statistics and Research. Coronavirus Pandemic (COVID-19). https://ourworldindata.org/coronavirus [Accessed 26 December 2020].
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous